Lifeboat Foundation

A summary of the sequel trial for a cocktail of drugs that originally turned back epigenetic clocks by 2.5 years. I do wonder what effect plasma filtering has on the thymus if any.

In this video we review the TRIIM study and look at the trial document for TRIIM-X, the extension study that Dr. Fahy is now conducting.

Continue reading “TRIIM-X 2nd Phase Clinical Trial For Reversing Human Aging | Study Review” »

Original Article from The New England Journal of Medicine — Neuroprosthesis for Decoding Speech in a Paralyzed Person with Anarthria.

Dr. Moses, Mr. Metzger, and Ms. Liu contributed equally to this article.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

Continue reading “Neuroprosthesis for Decoding Speech in a Paralyzed Person with Anarthria” »

Using high-powered imaging, the researchers were able to see, for the first time, that immune cells called microglia were not just removing damaged material after experimental seizures but actually appeared to be healing damaged neurons.

Summary: Microglia do not only remove damaged materials following a seizure, they also appear to heal damaged neurons.

Source: University of Virginia

Continue reading “Brain-Repair Discovery Could Lead to New Epilepsy Treatments” »

Summary: A novel helmet that generates a noninvasive oscillating magnetic field was able to reduce tumor mass by 31% in a glioblastoma brain cancer patient.

Source: Houston Methodist.

Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumor by more than a third using a helmet generating a noninvasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home. The 53-year-old patient died from an unrelated injury about a month into the treatment, but during that short time, 31% of the tumor mass disappeared. The autopsy of his brain confirmed the rapid response to the treatment.

Late last year, a French company called Carmat received approval in Europe for its total artificial heart. It’s exactly what it sounds like: a heart made of synthetic and biological materials intended for implantation into people who need heart transplants. Now, just half a year later, the first US patient has received one of the hearts.

The transplant took place last week in a 39-year-old man at Duke University Hospital in North Carolina. The man didn’t go to the hospital expecting to have a heart transplant, but it ended up saving his life.

Continue reading “‘Next-Generation’ Total Artificial Heart Successfully Transplanted into First US Patient” »

Good day to you all.

Sirtuins are once again, making headlines. From a longer lifespan, again, through to helping old and dormant hair follicles to grow new hair, and of course a discourse between certain personalities on twitter, they continue to stimulate the interest and promise so much…

Continue reading “Sirtuins Anti Aging. Revisited. What they are. Why you should care. How you can benefit” »

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 and rapidly spread to other provinces in China as well as other countries. In this study, 262 patients diagnosed with moderate to severe SARS-CoV-2 pneumonia in Wuhan, China, were analyzed. Data were compared between survivors and nonsurvivors. Of all the 262 patients, 23 (8.8%) patients died and 239 (91.2%) were discharged. The median age was 63.5 years and 46.9% of patients were male. The main complaints were fever (83.6%), cough (63.4%), and fatigue (49.2%) in the surviving group, while there were more complaints of dyspnea (39.1%) and shortness of breath (56.5%) in the nonsurviving group. The main comorbidities were hypertension (35.5%), diabetes mellitus (16.4%), and coronary artery disease (9.9%). Morbidity is higher in elderly patients with more comorbidities. Patients were mainly treated with nasal cannula (93.9%), while the nonsurviving group received more invasive mechanical ventilation (39.1%). Arbidol (80.9%), ribavirin (36.6%), oseltamivir (38.9%), interferon (16.4%), and ganciclovir (14.5%) were used for the antiviral treatment. In the nonsurviving group, the number of white blood cells (WBC) was significantly increased and lymphocytes were decreased, and lymphopenia was more common. The levels of aspartate transaminase (AST), brain natriuretic peptide (BNP), creatine kinase isoenzyme MB (CK-MB), lactate dehydrogenase (LDH), and C-reactive protein (CRP) were also significantly increased in the nonsurviving group. The adjusted hazard ratios (HRs) for association of known variables for all-cause mortality due to the coronavirus disease 2019 were 2.467 (95% confidence interval[CI], 1.007−6.044; p = 0.048) for shortness of breath and 1.025 (95% CI, 1.001−1.049; p = 0.042) for AST. Elderly patients with more comorbidities and complaints of dyspnea and shortness of breath had increased risk of death. Patients with lymphopenia and high levels of WBC, AST, BNP, CK-MB, LDH, and CRP may be more likely to deteriorate.

Human Gene Therapy.

Tetra’s trial will be the first worldwide drug which involves the use of an injectable sterile synthetic cannabinoid in patients infected by COVID-19. Tetra will use this study to demonstrate that its ARDS-003 drug can help prevent the acute respiratory distress seen in serious complications of COVID-19.

The proposed study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of ARDS-003 in hospitalized COVID-19 patients with pneumonia and at risk of developing acute respiratory distress syndrome.

Seeking guidance on clinical study protocol to be conducted in patients with COVID-19 is a pre-requisite of the Health Canada regulatory process for COVID-related trials. The Office of Clinical Trials of Health Canada’s Therapeutic Products Directorate acknowledged that Tetra’s extensive nonclinical data, including genotoxicity, safety pharmacology and toxicities studies, assessing the safety and pharmacokinetic profile of the investigational drug meet the authority’s requirements for a New Molecular Entity and granted the Company the approval for filing a clinical trial application in patients infected with Sars-CoV-2 (COVID-19). The authorities also agreed on the proposed study design, target population, and primary and secondary objectives and endpoints of the study in severe COVID-19 patients. To this end, contingent to Health Canada’s accelerated review process for Covid-related trials, the Company’s drug ARDS-003, will be evaluated in COVID-19 patients.

When an infant presented mysterious symptoms, doctors sequenced his genome — and got answers in under two days.